Product Images Lisdexamfetamine Dimesylate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Lisdexamfetamine Dimesylate NDC 72162-2456 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl721622456
This is a package insert for Lisdexamfetamine dimesylate 50 mg capsules, equivalent to 28.9 mg of lisdexamfetamine. It provides information on dosage and storage conditions, and includes details for pharmacists on dispensing the medication to patients. The medication guide and manufacturer information are also included.*
Chemical Structure - lisdexcaps 01
Figure 1 - lisdexcaps 02
This text provides information about a special population categorized by gender (Male/Female) and age groups (65 years and above). It also includes different levels of renal impairment such as mild, moderate, severe, and end-stage renal disease. Additionally, it mentions fold change and 90% CI related to a reference point.*
Figure 2 - lisdexcaps 03
Figure 3 - lisdexcaps 04
This is not readable text.*
Figure 4 - lisdexcaps 05
This text provides information about LS Mean (SE) SKAMP Deportment Scores for Placebo and Lisdexamfetamine over time post-dose. The data appears to be showing scores at 0, 2, and 5 hours post-dose for both treatment groups. The text does not provide a full description but gives a glimpse into a study or experiment comparing the two treatments for SKAMP Deportment Scores.*
Figure 5 - lisdexcaps 06
Figure 6 - lisdexcaps 07
This text provides information about LS Mean (SE) PERMP Total Scores for both Phacebo and Lisdexamfetamine over a period of time post-dose (hours). The scores range from 330 to 250 with time points at 4, 8, 12, and 14 hours post-dose. It seems to be a numerical data table related to the evaluation of the two treatments.*
Figure 7 - lisdexcaps 08
This is a data table showing the proportion of subjects with relapse/treatment failure over time (days after randomization) for lisdexamfetamine.*
Figure 8 - lisdexcaps 09
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
